NCT06431971View on ClinicalTrials.gov

Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Parkinson Disease
Interventions
DRUG

Talineuren

Talineuren infusion weekly

DRUG

Placebo

Placebo infusion weekly

Trial Locations (1)

3510

Neurologisches Institut Konolfingen, Konolfingen

All Listed Sponsors
lead

InnoMedica Schweiz AG

INDUSTRY

NCT06431971 - Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease | Biotech Hunter | Biotech Hunter